By Andrew Schulman – Technology Networks
Why do we need allogeneic therapies when autologous therapies have enjoyed such success?
The lessons learned from the development and manufacture of autologous cell therapies are helping lay a solid groundwork for the high potential and exciting field of allogeneic cell therapies. While the world focused on creating and distributing COVID-19 vaccines, a segment of the biotech industry kept pushing for the future generation of cell therapies. Now, the combination of lessons learned, momentum, and collaborative spirit will help this field become successful.
